ClinicalTrials.gg
TerminatedNCT06974734Updated Apr 23, 2026

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

A Phase 1 interventional study of PF-08046037 and sasanlimab in Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal and Malignant Melanoma, sponsored by Pfizer. Terminated at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Why this study was terminated
The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
124th of 136
8 · median 79
Started
2025
with 7 others
Phase 1
56 of 158
6 open now
Registered
149th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 124th largest by enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2025, is one of 56 in phase 1, and was the 149th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.

This study is seeking participants who:

  • have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, or pancreatic ductal adenocarcinoma (PDAC);
  • are able to provide tumor tissue samples;
  • have measurable disease. All participants will receive while at the clinic PF-08046037 alone as an intravenous (IV) infusion (given directly into a vein) or with sasanlimab as a subcutaneous (SQ) injection (given under the skin) once every 3 weeks.

Participants will continue to take the study drug(s) until their cancer is no longer responding or if the patient cannot safely take them. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

03

Conditions studied

  • Carcinoma, Non Small Cell Lung
  • Carcinoma, Pancreatic Ductal
  • Malignant Melanoma
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Keywords

  • Advanced solid tumors
  • NSCLC
  • PDAC
  • HNSCC
  • ISAC
  • ADC
  • PD-L1 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

This study is seeking participants who have the following tumor types and can provide tumor tissue samples as per below.

  1. Tumor types

    • Monotherapy Dose Escalation (Part 1a) and Optimization (Part 2a) cohorts

      • Advanced or NSCLC, HNSCC, melanoma, or PDAC
      • Must have progressive disease following at least 1 prior approved systemic therapy
    • Monotherapy Dose Expansion (Part 3a)

      • Advanced or metastatic NSCLC or PDAC
    • Combination Safety Evaluation (Part 1b) and Dose Optimization (Part 2b)

      • Advanced or metastatic NSCLC or HNSCC
      • May be either a) not received prior immunotherapy for the tumor type OR b) relapse/ after prior immunotherapy
    • Combination Dose Expansion (Part 3b)

      • Unresectable locally advanced or metastatic HNSCC or NSCLC
      • Must not have received prior systemic cytotoxic therapy in the locally advanced or metastatic setting ( setting)
      • Must be treatment naïve to any immunotherapy
      • NSCLC must have expression TPS >=50%
      • HNSCC must have PD-L1 expression CPS >=1
  2. Tissue requirement

    • Part 1 at lower doses: sufficient collected within 12 months of enrollment for submission to central laboratory
    • Part 1 at higher doses: de novo baseline tumor biopsy or archival tissue within 12 months of enrollment
    • Part 1 backfill: de novo baseline and on-treatment tumor biopsies are required
    • Part 2 and 3: de novo baseline or archival tissue within 6 months of enrollment
    • Part 2 and 3: mandatory on-treatment tumor biopsy, if required by sponsor
  3. per v1.1

Participants who meet the following might not be able to participate.

  1. History of Grade >=3 immune mediated AE related to prior immune modulatory therapy and required therapy
  2. Active or prior disease that might deteriorate when receiving an immunostimulatory agent
  3. History of uveitis within the preceding 6 months
  4. Grade >=3 neurodegenerative disease
  5. Grade 3 or higher pulmonary disease unrelated to underlying
  6. Previous exposure to an immunostimulatory antibody conjugate or systemic TLR agonist
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Part 1a

    PF-08046037 monotherapy dose escalation

    Drug: PF-08046037

  • Experimental
    Part 2a

    PF-08046037 monotherapy dose optimization

    Drug: PF-08046037

  • Experimental
    Part 3a

    PF-08046037 monotherapy dose expansion

    Drug: PF-08046037

  • Experimental
    Part 1b

    PF-08046037 +sasanlimab dose escalation

    Drug: PF-08046037 · Drug: sasanlimab

  • Experimental
    Part 2b

    PF-08046037 + sasanlimab dose optimization

    Drug: PF-08046037 · Drug: sasanlimab

  • Experimental
    Part 3b

    PF-08046037 + sasanlimab dose expansion

    Drug: PF-08046037 · Drug: sasanlimab

Interventions

  • DrugPF-08046037

    Given into the vein (IV; intravenous)

    Also known as: SGN-PDL1iT

  • Given under the skin (SQ; subcutaneous)

    Also known as: PF-06801591

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  2. Number of participants with laboratory abnormalities

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  3. Number of dose modifications due to AEs

    Time frame: Through end of treatment up to approximately 2 years

  4. Number of participants with dose-limiting toxicities (DLTs)

    Time frame: Up to 21 days

  5. Number of participants with DLTs by dose level

    Time frame: Up to 21 days

Secondary outcomes

  1. Pharmacokinetic (PK) parameter - Area under the concentration-time curve (AUC)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  2. PK parameter - Maximum concentration (Cmax)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  3. PK parameter - Time to maximum concentration (Tmax)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  4. PK parameter - t1/2

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  5. PK parameter - Trough concentration (Ctrough)

    PK endpoint

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  6. Number of participants with antidrug antibodies (ADAs)

    Time frame: Through 30-37 days after the last study treatment, up to approximately 2 years

  7. Objective response rate (ORR)

    The objective response rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) which is subsequently confirmed as assessed according to Response Evaluation in Solid Tumors (RECIST) v1.1.

    Time frame: Through end of study and up to approximately 2 years

  8. Best overall response

    The best overall response for a participant will be determined by the order of confirmed CR, confirmed PR, stable disease (SD), progressive disease (PD), not evaluable (NE) or not applicable (NA) per RECIST v1.1.

    Time frame: Through end of study and up to approximately 2 years

  9. Duration of response (DOR)

    DOR is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per RECIST v1.1 or to death due to any cause

    Time frame: Through end of study and up to approximately 2 years

  10. Progression-free survival (PFS)

    PFS is defined as the time from start of PF-08046037 to first documentation of disease progression (based on radiographic assessments per RECIST v1.1) or death due to any cause, whichever comes first

    Time frame: Through end of study and up to approximately 2 years

  11. Overall survival (OS)

    OS is defined as the time from start of PF-08046037 to date of death due to any cause

    Time frame: Through end of study and up to approximately 2 years

  12. Percent change of cells within tumors based on multiplex immunofluorescence

    This measure will assess the number of immune cells, PD-1, PD-L1, and TLR7 expression within the tumor microenvironment.

    Time frame: Through end of study and up to approximately 2 years

07

Study locations

15 sites
  • Presbyterian/ St. Lukes Medical Center
    Denver, Colorado 80218, United States
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado 80218, United States
  • Smilow Cancer Hospital - Yale New Haven Health
    New Haven, Connecticut 06510, United States
  • Yale - New Haven Hospital - Yale Cancer Center
    New Haven, Connecticut 06510, United States
  • Smilow Cancer Hospital Phase 1 Unit
    New Haven, Connecticut 06511, United States
  • Smilow Cancer Hospital - Trumbull
    Trumbull, Connecticut 06611, United States
  • Community Health Network, Inc
    Indianapolis, Indiana 46219, United States
  • Community Health Network, Inc.
    Indianapolis, Indiana 46227, United States
  • Community Health Network, Inc.
    Indianapolis, Indiana 46250, United States
  • Community Health Network, Inc.
    Indianapolis, Indiana 46256, United States
  • START Midwest
    Grand Rapids, Michigan 49546, United States
  • Sarah Cannon Research Institute - Pharmacy
    Nashville, Tennessee 37203, United States
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
  • Tristar Centennial Medical Center
    Nashville, Tennessee 37203, United States
  • Pan American Center for Oncology Trials, LLC
    Rio Piedras, 00935, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Mar 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 16, 2025
StartActual
May 6, 2025
Primary completionActual
Mar 20, 2026
CompletionActual
Mar 31, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974734
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 16, 2025
Start date
May 6, 2025
Primary completion
Mar 20, 2026
Completion
Mar 31, 2026
Last update
Apr 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion